No results for ‘’
Anthem Biosciences Ltd
NSE: ANTHEM BSE: 544449
₹769.10
(1.46%)
Tue, 26 May 2026, 05:44 pm
Market Cap438.28B
PE Ratio73.54
Dividend0
Health Technology
Biotechnology
24.5KCompany History
2006
- Incorporation of our Company.
2007
- Commenced operations of our Company at Unit I and set up a custom synthesis plant with a capacity of 6 KL.
2008
- Commencement of the discovery biology services with a fermentation capacity of 2 KL.
2010
- Expanded the custom synthesis plant set up at Unit I increasing its capacity from 6 KL to 24 KL.
2013
- Received the first USFDA audit approval for Unit I.
2016
- Set up a high potent lab at Unit I - Bommasandra Facility.
2017
- Our Company amalgamated with Anthem Cellutions (India) Private Limited by way of an acquisition of 100% of its share capital.
- Set up a solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1.
- Commenced operations of our Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL.
- Received the second USFDA audit approval for Unit I.
2018
- Anthem Cellutions (India) Private Limited amalgamated into our Company.
2019
- Received the third USFDA approval for Unit I.
- Set up a flow chemistry lab at Unit I.
2020
- Commenced operations in biological facility 2 earmarked for a specific client.
2022
- Expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL.
2023
- Received the first USFDA audit approval and first therapeutic goods administration audit for Unit II.
- Addition of Oligonucleotide lab in Unit I.
- Set a cGMP scale continuous flow manufacturing facility for Unit II.
2024
- Received the second USFDA audit approval for Unit II.
- Received the first ANVISA audit approval for Unit I.
- Received the first ANVISA audit approval for Unit II.
- Commenced operations of Neoanthem Lifesciences Private Limited, at Unit III.
- Fermentation capacity expanded to 140 KL at Unit II.
- Conversion of our Company into a public limited company, under the name Anthem Biosciences Limited.
2025
- Received the fourth USFDA approval for Unit I.